Aerie Pharmaceuticals

Aeroe Pharmaceuticals Inc.
Company typeSubsidiary
Nasdaq: AERI
Industry
  • Pharmaceuticals
  • Ophthalmology
Founded2005 (2005)
Founders
  • David L. Epstein
  • Casey C. Kopczynski
HeadquartersDurham, North Carolina, U.S.
ParentAlcon
Websiteaeriepharma.com

Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily therapies for lowering intraocular pressure with mechanisms to treat patients with glaucoma or ocular hypertension.

In August 2022, Swiss eye-care firm Alcon agreed to buy Aerie Pharmaceuticals for US$770 million. The acquisition completed in November 2022.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.